Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2023 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
April 17, 2023 13:30 ET
|
Caribou Biosciences, Inc.
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
March 20, 2023 01:45 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
March 13, 2023 01:45 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 09, 2023 17:09 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling...
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
March 06, 2023 01:45 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
February 14, 2023 16:00 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CRBU Class Action Lawsuit Announced: Johnson Fistel Encourages Shareholders to Submit Their Caribou Biosciences Information
February 11, 2023 11:02 ET
|
Johnson Fistel, LLP
SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Caribou Biosciences, Inc....
Lawsuit filed for Investors with substantial Losses in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares announced by the Shareholders Foundation
February 10, 2023 22:36 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares. Investors...